Blocking CMV transmission through the human milk metabolome and microbiome - Despite decades-long research and multiple trials, there is no licensed vaccine against Cytomegalovirus (CMV)
yet, urging efforts to better understand its transmission dynamics. CMV is a frequent cause of tissue-invasive
disease in infants and immunocompromised individuals, and transmission happens easily and through contact
with various body fluids. Among transmission modes, CMV transmission via human milk (HM) is recognized to
have the largest global impact on population prevalence. Factors determining CMV transmission remain largely
unknown, including CMV interactions with HM microbiota and metabolites. In general, commensal microbiota
can greatly impact sensitivity to viral infections while, metabolites, such as human milk oligosaccharides (HMOs),
not only feed human microbiota but can also act as soluble decoy receptors, blocking the attachment of viral
pathogens to epithelial cells. Additionally, short chain and medium chain fatty acids are products of microbial
fermentation, known to influence immune responses, and microbiota can also produce antivirals through
secondary metabolism. Therefore, the objective of this proposal is to better define CMV transmission dynamics,
considering different factors and timescales, and to systematically and quantitatively study the role and
interactions of the HM metabolome and microbiome influencing CMV transmission from women to their infants.
Our preliminary data readily shows that CMV seronegative and seropositive mothers have distinct HM
microbiome and metabolome ecologies. In particular, we found clear differences distinguishing seropositive
mothers that are non-shedding, shedding but not transmitting, and shedding and transmitting CMV. These results
led to the central hypothesis, which is that certain combinations of HM microbiota and metabolites prevent CMV
transmissions, and that these combinations vary among individual dyads, but follow traceable and reproducible
patterns. We propose to test the central hypothesis by pursuing the following three specific aims: (1) Determine
CMV transmission dynamics with high sample density and HM microbiome ecologies underlying CMV
transmission versus non-transmission; (2) Identify and validate key metabolites involved in CMV transmission
and non-transmission; and (3) Define causality and identify molecular mechanisms of CMV transmission
inhibition assisted by mathematical modeling and artificial intelligence. Collectively, our proposed research will
broadly impact the field by elucidating CMV-host interactions and CMV transmission dynamics in various time
scales, validating factors blocking CMV transmission, and providing models and tools to help advance the arrival
of clinical resource. These studies also have the potential to lay the groundwork for, and translate into, rational
design of personalized HM and microbiome-metabolome interventions without replacing HM.
